---
title: "APLS.US (APLS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/APLS.US/news.md"
symbol: "APLS.US"
name: "APLS.US"
parent: "https://longbridge.com/en/quote/APLS.US.md"
datetime: "2026-05-20T15:43:15.176Z"
locales:
  - [en](https://longbridge.com/en/quote/APLS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/APLS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/APLS.US/news.md)
---

# APLS.US (APLS.US) — Related News

### [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)
*2026-05-14T23:10:02.000Z*
> Biogen is expanding its focus on immunology, particularly in lupus and kidney disease, as part of its growth strategy. A

### [Apellis Completes Biogen Merger and Goes Private](https://longbridge.com/en/news/286424730.md)
*2026-05-14T13:22:42.000Z*
> Apellis Pharmaceuticals has completed its merger with Biogen, transitioning into a privately held subsidiary. As part of

### [RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)](https://longbridge.com/en/news/285944432.md)
*2026-05-11T12:41:55.000Z*
> RBC Capital's Lisa Walter has maintained a Hold rating on Apellis Pharmaceuticals (APLS) with a price target of $41.00, 

### [Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Beats Estimates By $0.53 EPS](https://longbridge.com/en/news/285663598.md)
*2026-05-08T04:35:28.000Z*
> Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $0.15 per share, exceeding estimates by $0.53. The 

### [Apellis Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 268.3 M](https://longbridge.com/en/news/285534234.md)
*2026-05-07T10:57:57.000Z*
### [Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High  - Here's What Happened](https://longbridge.com/en/news/285415811.md)
*2026-05-06T17:17:57.000Z*
> Apellis Pharmaceuticals (NASDAQ:APLS) reached a new 52-week high of $41.05, closing at $40.9750 with a trading volume of

### [XBI, APLS, TVTX, RVMD: ETF Outflow Alert](https://longbridge.com/en/news/285400841.md)
*2026-05-06T15:00:29.000Z*
> The SPDR S&P Biotech ETF (XBI) has experienced a significant outflow of approximately $291 million, marking a 3.4% decre

### [Top 3 Health Care Stocks That May Collapse This Month](https://longbridge.com/en/news/285076294.md)
*2026-05-04T12:44:43.000Z*
> Three healthcare stocks, Avanos Medical (AVNS), Apellis Pharmaceuticals (APLS), and Cerus Corp (CERS), are showing signs

### [Apellis Updates Executive Separation Plan Amid Biogen Merger](https://longbridge.com/en/news/285070148.md)
*2026-05-04T11:33:02.000Z*
> Apellis Pharmaceuticals has updated its Executive Separation Benefits and Retention Plan in light of its merger with Bio